| Literature DB >> 31097999 |
Douglas W Thomson1, Daniel Poeckel1, Nico Zinn1, Christina Rau1, Katrin Strohmer1, Anne J Wagner1, Alan P Graves2, Jessica Perrin1, Marcus Bantscheff1, Birgit Duempelfeld1, Viera Kasparcova3, Joshi M Ramanjulu3, G Scott Pesiridis3, Marcel Muelbaier1, Giovanna Bergamini1.
Abstract
The serine/threonine protein kinase TBK1 (Tank-binding Kinase-1) is a noncanonical member of the IkB kinase (IKK) family. This kinase regulates signaling pathways in innate immunity, oncogenesis, energy homeostasis, autophagy, and neuroinflammation. Herein, we report the discovery and characterization of a novel potent and highly selective TBK1 inhibitor, GSK8612. In cellular assays, this small molecule inhibited toll-like receptor (TLR)3-induced interferon regulatory factor (IRF)3 phosphorylation in Ramos cells and type I interferon (IFN) secretion in primary human mononuclear cells. In THP1 cells, GSK8612 was able to inhibit secretion of interferon beta (IFNβ) in response to dsDNA and cGAMP, the natural ligand for STING. GSK8612 is a TBK1 small molecule inhibitor displaying an excellent selectivity profile and therefore represents an ideal probe to further dissect the biology of TBK1 in models of immunity, neuroinflammation, obesity, or cancer.Entities:
Year: 2019 PMID: 31097999 PMCID: PMC6512007 DOI: 10.1021/acsmedchemlett.9b00027
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345